目的 探讨西利宾胺预防抗结核药引起肝损害的疗效.方法 在我所接受抗结核治疗的患者486人,分为观察组,238例,对照组248例,两组均给予2RHZE/4RH方案抗结核治疗,观察组同时加服西利宾胺治疗,对照组加服肌苷治疗.结果 观察组发生肝损害21例(21/238)占8.8％,对照组发生肝损害64例(64/248)占25.8％两组比较P＜0.05.结论 西利宾胺能较好预防治疗抗结核药引起的肝损害,值得临床推广运用.%Objective To explore the therapeutic effect of Silymarin in the prevention of hepatic lesion induced by antituberculot-ic. Method 486 patients which received anti - TB treaetment were randomly divided into the observation group(238 cases) and the control group(248 cases). The two groups all received anti -TB treaetment of 2RHZE/4RH, meanwhile the observation group plus Silymarin and the control plus inosine. Result 21 cases with hepatic lesion in the observation group(21/238, 8. 8% ) , 64 cases with hepatic lesion in the control group (64/248, 18%), and there was significant difference compared with two groups ( P < 0. 05 ). Conclusion Silymarin can prevent from hepatic lesion induced by antituberculotic, which is worthy of being recommended in clinical practice.
展开▼
